Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOncimmune Regulatory News (ONC)

  • This share is currently suspended. It was suspended at a price of 1.2699
  • There is currently no data for ONC

PDMR Dealing

14 Jan 2021 09:49

RNS Number : 6923L
Oncimmune Holdings PLC
14 January 2021
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

PDMR Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified on 13 January 2021 that Genostics Company Limited ("Genostics"), a Person Closely Associated ("PCA") (as that term is defined in the EU Market Abuse Regulation ("MAR")) with Dr Cheung To, a Non-Executive Director of the Company, has sold ordinary shares of £0.01 each in the Company ("Ordinary Shares") as follows:

 

Date

No Ordinary Shares

Price (£)

11 December 2020

10,000

1.65

14 December 2020

30,000

1.675

21 December 2020

5,000

1.70

5 January 2021

50,000

1.70

5 January 2021

50,000

1.75

8 January 2021

10,000

1.85

11 January 2021

40,000

1.85

Total

195,000

 

Following this transaction, Genostics has a total interest in the Company of 6,215,256 Ordinary Shares, representing approximately 9.8 per cent. of the Company's issued Ordinary Share capital.  

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Genostics Company Limited

2

 

Reason for the notification

a)

 

Position/status

 

PCA of Dr Cheung To, Non-Executive Director of the Company

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Disposal of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.65

10,000

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction

 

11 December 2020

f)

 

Place of the transaction

London stock exchange, AIM

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Disposal of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.675

30,000

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction

 

14 December 2020

f)

 

Place of the transaction

London stock exchange, AIM

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Disposal of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.70

5,000

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction

 

21 December 2020

f)

 

Place of the transaction

London stock exchange, AIM

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Disposal of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.70

50,000

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction

 

5 January 2021

f)

 

Place of the transaction

London stock exchange, AIM

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Disposal of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.75

50,000

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction

 

5 January 2021

f)

 

Place of the transaction

London stock exchange, AIM

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Disposal of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.85

10,000

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction

 

8 January 2021

f)

 

Place of the transaction

London stock exchange, AIM

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 

Identification code

ISIN: GB00BYQ94H38

b)

 

Nature of the transaction

 

Disposal of shares

c)

 

Price(s) and volume(s)

Price

Volume

£1.85

40,000

d)

 

Aggregated information

- Aggregated volume

Same as above

- Price

e)

 

Date of the transaction

 

11 January 2021

f)

 

Place of the transaction

London stock exchange, AIM

 

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, General Counsel and Company Secretary

contact@oncimmune.com  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHDKQBQCBKKFDD
Date   Source Headline
20th May 202212:11 pmRNSHolding(s) in Company
18th May 202211:46 amRNSHolding(s) in Company
5th May 20225:32 pmRNSHolding(s) in Company
3rd May 20226:10 pmRNSHolding(s) in Company
26th Apr 20224:26 pmRNSHolding(s) in Company
21st Apr 20227:00 amRNSQueen’s Award for Enterprise in Innovation 2022
14th Apr 202212:24 pmRNSExercise of Options, PDMR Dealing and TVR
8th Apr 20227:00 amRNSTwo further ImmunoINSIGHTS contracts signed
4th Apr 20222:43 pmRNSHolding(s) in Company
29th Mar 20224:46 pmRNSExercise of Options, PDMR Dealing and TVR
18th Mar 20223:01 pmRNSHolding(s) in Company
16th Mar 20227:00 amRNSBlock Listing Six Monthly Return
15th Mar 20227:00 amRNSExercise of Warrants and Total Voting Rights
9th Mar 20224:08 pmRNSHolding(s) in Company
7th Mar 20222:10 pmRNSPDMR Dealing
7th Mar 20227:00 amRNSFollow-on contract to validate previous profiling
4th Mar 20227:00 amRNSImmunoINSIGHTS contract signed with global pharma
1st Mar 20227:00 amRNSImmunoINSIGHTS and Synexa partnership
28th Feb 20227:05 amRNSInterim Results
28th Feb 20227:00 amRNSContract signed with Verily Life Sciences
25th Feb 20227:00 amRNSNotice of Half Year Results
21st Feb 20223:14 pmRNSHolding(s) in Company
17th Feb 20227:00 amRNSEarlyCDT Lung approved and adopted in Aragon Spain
15th Feb 20227:00 amRNSImmunoINSIGHTS commercial update
31st Dec 20217:00 amRNSResults from COVID-19 autoantibody profiling panel
24th Dec 20217:00 amRNSPDMR Dealing
22nd Dec 202111:10 amRNSGrant of Options and PDMR Dealing
21st Dec 202111:34 amRNSPDMR Dealing
21st Dec 20217:00 amRNSImmunoINSIGHTS commercial update
20th Dec 20213:13 pmRNSTotal Voting Rights
7th Dec 20217:00 amRNSCommercial momentum in ImmunoINSIGHTS
26th Nov 20214:41 pmRNSSecond Price Monitoring Extn
26th Nov 20214:36 pmRNSPrice Monitoring Extension
26th Nov 202110:36 amRNSResults of Annual General Meeting
3rd Nov 20217:00 amRNSNotice of AGM and posting of Annual Report
2nd Nov 20217:00 amRNSFull year results and progress update
2nd Nov 20217:00 amRNSChange of Adviser
27th Oct 20214:35 pmRNSPrice Monitoring Extension
25th Oct 20214:40 pmRNSSecond Price Monitoring Extn
25th Oct 20214:35 pmRNSPrice Monitoring Extension
25th Oct 20217:00 amRNSNotice of Full Year results
20th Sep 20217:00 amRNSAgreement with pharma company to profile patients
15th Sep 202111:08 amRNSBlock Listing Six Monthly Return
23rd Aug 20217:00 amRNSThree-year follow-up data for the ECLS trial
23rd Jul 20217:00 amRNSAgreement signed with major cancer center
22nd Jul 20217:00 amRNSValidation of ImmunoINSIGHTS service in COVID-19
1st Jul 20217:00 amRNSTotal Voting Rights
8th Jun 20217:00 amRNSFull Year Trading Update
28th May 20217:30 amRNSNotice of FY21 Trading Update
5th May 20217:03 amRNSReturn of China Rights to EarlyCDT

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.